Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

Of course, some of the rally’s nothing more than the left-behind stocks playing catch up. The drug stocks had a rare day in ...

Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the continued generic impact on ...

In regular trading, the blue-chip Dow advanced 400 points, while the S&P 500 slipped 0.1%. The Nasdaq Composite lost 0.8% as ...

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

The stock's rise snapped a four-day losing streak.

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by ...

Blue-chip dividend stocks are typically safe, and many are reasonably priced. Five may be incredible ideas for growth and income investors.

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The sto ...

GAMMA Investing LLC recently increased its stake in Bristol Myers Squibb by 18.8%, acquiring 6,267 additional shares. This ...